Bafna Pharmaceuticals Ltd (BAFNAPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 852453, "name": "Bafna Pharma.", "stock_name": "Bafna Pharma.", "full_name": "Bafna Pharmaceuticals Ltd", "name_url": "stocks-analysis/bafna-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "107.50", "chg": -1.4, "chgp": "-1.29%", "dir": -1, "prev_price": "108.90", "mcapval": "253.00 Cr", "mcap": "Micro Cap", "scripcode": 532989, "symbol": "BAFNAPH", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE878I01022", "curr_date": "Mar 05", "curr_time": "", "bse_nse_vol": "11.74 k", "exc_status": "Active", "traded_date": "Mar 05, 2026", "traded_date_str": "2026 03 05", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Bafna Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3862083", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_mojoScore_3862083.png", "date": "2026-02-28 10:10:14", "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 28 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Bafna Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3844142", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_mojoScore_3844142.png", "date": "2026-02-17 10:10:38", "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook." }, { "title": "Bafna Pharmaceuticals Gains 5.69%: 3 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-gains-569-3-key-factors-driving-the-weeks-momentum-3839641", "imagepath": "", "date": "2026-02-14 14:06:23", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>9 Feb:</strong> Upper circuit hit at ₹121.80 (+5.0%) amid strong buying pressure</p>\n <p><strong>10 Feb:</strong> Another upper circuit close at ₹127.85 (+4.97%) with regulatory freeze</p>\n <p><strong>11 Feb:</strong> Q3 FY26 results reveal profitability concerns despite stable revenue</p>\n <p><strong>13 Feb:</strong> Week closes at ₹123.50 (-4.78% on day), still up 5.69% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹116.85</div></div>\n <div class=\"stat-item\"><div cl..." }, { "title": "Are Bafna Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-bafna-pharmaceuticals-ltd-latest-results-good-or-bad-3835860", "imagepath": "", "date": "2026-02-12 19:58:15", "description": "Bafna Pharmaceuticals Ltd's latest financial results for Q3 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹1.84 crores, which reflects a quarter-on-quarter decline of 41.03%. This decline is concerning, especially when viewed alongside the operating margin, which has compressed to 7.97%, marking the lowest level in four quarters. This indicates challenges in maintaining profitability and operational efficiency.\n\nIn contrast, the half-year performance showed a year-on-year growth of 38.55% in profit after tax, suggesting that while there may be potential for recovery, recent quarterly results have raised significant concerns regarding margin sustainability and operational effectiveness. The reliance on non-operating income, which constituted 66.30% of profit before tax, further complicates the assessment of the company's core operational health.\n\nThe historica..." }, { "title": "Bafna Pharmaceuticals Q3 FY26: Profitability Concerns Mount Despite Revenue Stability", "link": "https://www.marketsmojo.com/news/result-analysis/bafna-pharmaceuticals-q3-fy26-profitability-concerns-mount-despite-revenue-stability-3833872", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_quaterlyResult_3833872.png", "date": "2026-02-11 20:06:40", "description": "Bafna Pharmaceuticals Ltd., a Chennai-based pharmaceutical formulations manufacturer, has posted concerning profitability trends in Q3 FY26, with net profit declining 30.40% sequentially to ₹1.84 crores despite relatively stable revenue performance. The micro-cap pharmaceutical company, with a market capitalisation of ₹308.00 crores, has seen its shares retreat 16.24% year-to-date to ₹130.00, reflecting growing investor scepticism about the sustainability of its recent turnaround efforts." }, { "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3830325", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_stocks_hitting_upper_circuit_3830325.png", "date": "2026-02-10 10:00:54", "description": "Bafna Pharmaceuticals Ltd surged to its upper circuit limit on 10 Feb 2026, registering a maximum daily gain of 4.97% and closing at ₹127.85. The stock’s robust performance was driven by intense buying interest, resulting in a regulatory freeze on further trading and highlighting unfilled demand in the market." }, { "title": "Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3828364", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_stocks_hitting_upper_circuit_3828364.png", "date": "2026-02-09 10:00:34", "description": "Bafna Pharmaceuticals Ltd (BE: 852453) surged to its upper circuit limit on 09 Feb 2026, closing at ₹121.8, marking a maximum daily gain of 5.0%. The stock demonstrated robust buying interest, outperforming its sector and broader market indices despite a backdrop of falling investor participation and regulatory trading restrictions." }, { "title": "When is the next results date for Bafna Pharmaceuticals Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-bafna-pharmaceuticals-ltd-3825253", "imagepath": "", "date": "2026-02-06 23:18:50", "description": "The next results date for Bafna Pharmaceuticals Ltd is scheduled for 11 February 2026...." }, { "title": "Bafna Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3824001", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BafnaPharmaceut_mojoScore_3824001.png", "date": "2026-02-06 10:11:09", "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." } ], "total": 275, "sid": "852453", "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "14-Feb-2026", "details": "Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31 2025 as published in Business Standard and Makkal Kural on February 13 2026.", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome For The Board Meeting Held On 11/02/2026", "datetime": "11-Feb-2026", "details": "The Board of Directors of the Company in the Meeting held on February 11 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Nine-Months ended on December 31 2025.", "source": "BSE" }, { "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025", "datetime": "11-Feb-2026", "details": "The Board of Directors of the Company in their Meeting held on February 11 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited Review Report for the Quarter and Nine Months ended on December 31 2025.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13", "dt": "2013-09-19", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

9 Feb: Upper circuit hit at ₹121.80 (+5.0%) amid strong buying pressure

10 Feb: Another upper circuit close at ₹127.85 (+4.97%) with regulatory freeze

11 Feb: Q3 FY26 results reveal profitability concerns despite stable revenue

13 Feb: Week closes at ₹123.50 (-4.78% on day), still up 5.69% for the week

Week Open

₹116.85

Read full news article

Are Bafna Pharmaceuticals Ltd latest results good or bad?

2026-02-12 19:58:15

Bafna Pharmaceuticals Ltd's latest financial results for Q3 FY26 reveal a complex picture of operational performance. The company reported a net profit of ₹1.84 crores, which reflects a quarter-on-quarter decline of 41.03%. This decline is concerning, especially when viewed alongside the operating margin, which has compressed to 7.97%, marking the lowest level in four quarters. This indicates challenges in maintaining profitability and operational efficiency. In contrast, the half-year performance showed a year-on-year growth of 38.55% in profit after tax, suggesting that while there may be potential for recovery, recent quarterly results have raised significant concerns regarding margin sustainability and operational effectiveness. The reliance on non-operating income, which constituted 66.30% of profit before tax, further complicates the assessment of the company's core operational health. The historica...

Read full news article

Bafna Pharmaceuticals Q3 FY26: Profitability Concerns Mount Despite Revenue Stability

2026-02-11 20:06:40

Bafna Pharmaceuticals Ltd., a Chennai-based pharmaceutical formulations manufacturer, has posted concerning profitability trends in Q3 FY26, with net profit declining 30.40% sequentially to ₹1.84 crores despite relatively stable revenue performance. The micro-cap pharmaceutical company, with a market capitalisation of ₹308.00 crores, has seen its shares retreat 16.24% year-to-date to ₹130.00, reflecting growing investor scepticism about the sustainability of its recent turnaround efforts.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-02-10 10:00:54

Bafna Pharmaceuticals Ltd surged to its upper circuit limit on 10 Feb 2026, registering a maximum daily gain of 4.97% and closing at ₹127.85. The stock’s robust performance was driven by intense buying interest, resulting in a regulatory freeze on further trading and highlighting unfilled demand in the market.

Read full news article

Bafna Pharmaceuticals Ltd Hits Upper Circuit Amid Strong Buying Pressure

2026-02-09 10:00:34

Bafna Pharmaceuticals Ltd (BE: 852453) surged to its upper circuit limit on 09 Feb 2026, closing at ₹121.8, marking a maximum daily gain of 5.0%. The stock demonstrated robust buying interest, outperforming its sector and broader market indices despite a backdrop of falling investor participation and regulatory trading restrictions.

Read full news article

When is the next results date for Bafna Pharmaceuticals Ltd?

2026-02-06 23:18:50

The next results date for Bafna Pharmaceuticals Ltd is scheduled for 11 February 2026....

Read full news article

Bafna Pharmaceuticals Ltd is Rated Sell

2026-02-06 10:11:09

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article